Genetic testing for detection of hereditary cancer risk
DOI:
https://doi.org/10.35381/s.v.v8i1.3849Keywords:
Genetic testing, genetic carrier screening, diagnostic techniques and procedures, (Source: DeCS)Abstract
Objective: To analyze genetic tests for detection of hereditary cancer risk. Method: Descriptive documentary. Conclusion: Genetic cancer is a form of cancer caused by inherited or acquired genetic alterations, which increase the susceptibility to develop malignant tumors. Genetic testing is an essential tool for identifying genetic mutations associated with cancer and assessing individual risk for the disease.
Downloads
References
LeSavage BL, Suhar RA, Broguiere N, Lutolf MP, Heilshorn SC. Next-generation cancer organoids. Nat Mater. 2022;21(2):143-159. https://doi.org/10.1038/s41563-021-01057-5
Orsolic I, Carrier A, Esteller M. Genetic and epigenetic defects of the RNA modification machinery in cancer. Trends Genet. 2023;39(1):74-88. https://doi.org/10.1016/j.tig.2022.10.004
Chavarri-Guerra Y, Slavin TP, Longoria-Lozano O, Weitzel JN. Genetic cancer predisposition syndromes among older adults. J Geriatr Oncol. 2020;11(7):1054-1060. https://doi.org/10.1016/j.jgo.2020.01.001
Nam AS, Chaligne R, Landau DA. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics. Nat Rev Genet. 2021;22(1):3-18. https://doi.org/10.1038/s41576-020-0265-5
Gadaleta E, Thorn GJ, Ross-Adams H, Jones LJ, Chelala C. Field cancerization in breast cancer. J Pathol. 2022;257(4):561-574. https://doi.org/10.1002/path.5902
Alexander JL, Johnston BJ, Smith TJ, et al. Low Referral Rates for Genetic Assessment of Patients With Multiple Adenomas in United Kingdom Bowel Cancer Screening Programs. Dis Colon Rectum. 2021;64(9):1058-1063. https://doi.org/10.1097/DCR.0000000000001972
Seferbekova Z, Lomakin A, Yates LR, Gerstung M. Spatial biology of cancer evolution. Nat Rev Genet. 2023;24(5):295-313. https://doi.org/10.1038/s41576-022-00553-x
Lin A, Sheltzer JM. Discovering and validating cancer genetic dependencies: approaches and pitfalls. Nat Rev Genet. 2020;21(11):671-682. https://doi.org/10.1038/s41576-020-0247-7
Luzón-Toro B, Fernández RM, Villalba-Benito L, Torroglosa A, Antiñolo G, Borrego S. Influencers on Thyroid Cancer Onset: Molecular Genetic Basis. Genes (Basel). 2019;10(11):913. https://doi.org/10.3390/genes10110913
Stanich PP, Hampel H. Many Polyps but Few Referrals: A Call to Assess and Improve Referral Rates for Colon Polyposis. Dis Colon Rectum. 2021;64(9):1035-1037. https://doi.org/10.1097/DCR.0000000000002161
Scudeler MM, Manóchio C, Braga Pinto AJ, Santos Cirino HD, da Silva CS, Rodrigues-Soares F. Breast cancer pharmacogenetics: a systematic review. Pharmacogenomics. 2023;24(2):107-122. https://doi.org/10.2217/pgs- 2022-0144
Carrot-Zhang J, Chambwe N, Damrauer JS, et al. Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell. 2020;37(5):639-654.e6. https://doi.org/10.1016/j.ccell.2020.04.012
Oesterreich S, Henry NL, Kidwell KM, et al. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. Breast Cancer Res Treat. 2015;154(2):263-273. https://doi.org/10.1007/s10549-015-3608-8
Kamdem LK, Xi J, Clark BL, et al. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion. Breast Cancer Res Treat. 2019;175(2):297-303. https://doi.org/10.1007/s10549-019-05158-3
Dempsey JM, Kidwell KM, Gersch CL, et al. Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. Pharmacogenomics. 2019;20(8):571-580. https://doi.org/10.2217/pgs-2019-0020
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Emily Dayana Guzmán-Ramos, Yessenia Estefanía Arellano-Oleas, Sandra Janneth Velásquez-Toro, Marcia Alexandra Silva-Mata
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
